|Mr. Jean-Christophe Tellier||CEO & Exec. Director||76k||N/A||1959|
|Mr. Detlef Thielgen||CFO & Exec. VP||N/A||N/A||1960|
|Dr. Dhavalkumar D. Patel||Exec. VP & Chief Scientific Officer||N/A||N/A||1961|
|Dr. Bharat Tewarie||Chief Marketing Officer & Exec. VP||N/A||N/A||1961|
|Prof. Iris Löw-Friedrich||Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP||N/A||N/A||1960|
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company's product pipeline includes Evenity for the treatment of osteoporosis; midazolam nasal spray to treat acute repetitive seizures; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 and UCB0159 for immunology; and UCB0599 and UCB0107 for neurology. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.
UCB SA’s ISS Governance QualityScore as of October 4, 2019 is 5. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 9; Compensation: 5.